Semaglutide API prices are falling sharply as global demand for weight-loss drugs like Ozempic and Wegovy drives rapid manufacturing expansion. With patents set to expire in key markets and Indian companies rolling out lower-priced generics, analysts expect additional price softening. The shift could widen access to these GLP-1 therapies for patients in the months ahead.
India’s weight-loss drug market is rapidly shifting as generic semaglutide becomes available after Novo Nordisk’s patent loss. The cheaper alternatives are already pressuring Eli Lilly’s sales while unlocking a surge in demand. With multiple Indian drugmakers racing to launch affordable options, the country’s obesity-treatment landscape is entering a new, more price-accessible phase.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Alembic Pharmaceuticals has received USFDA final approval for its generic methotrexate injection, a widely used medicine for multiple cancers and inflammatory conditions. The regulator greenlit key dosage formats and confirmed therapeutic equivalence to the reference Hospira product, clearing the way for Alembic to market the injectable in the US for cancers and conditions like rheumatoid arthritis and severe psoriasis.
Lupin has launched generic anti-diabetic tablets in the United States—dapagliflozin and metformin hydrochloride extended-release—after receiving FDA approval. The company says its product is bioequivalent to Xigduo XR, positioning the launch as a potential new option for diabetes patients seeking effective treatment in the US market.
Indian pharma’s US outlook has improved after years of pressure from price erosion and compliance hurdles. Drug shortages have temporarily slowed price erosion, while launches of key generic drugs have helped companies regain footing. Yet the real question is sustainability: will the same conditions hold, or will competition and supply normalization bring renewed margin stress?
Swipe through stories, personalise your feed, and save articles for later — all on the app.
